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Summary Two non-transformed human skin fibroblast strains, GM38 and 3437T, were found to be more
sensitive to the bioreductive alkylating agents mitomycin C (MMC) and porfiromycin (PM) under hypoxic
compared to aerobic conditions. One of these strains, 3437T, was 6-7 times more resistant to these agents
under aerobic exposure conditions, but was identical in sensitivity to the normal strain, GM38, under hypoxic
conditions. Aerobic 3437T cells demonstrated no increased resistance to cisplatin compared to the normal
strain, arguing against enhanced ability to repair DNA interstrand cross-links as the underlying explanation
for the mitomycin resistance. The aerobic resistance of 3437T was not altered by dicumarol, an inhibitor of
the enzyme DT-diaphorase which is believed to be involved in aerobic activation of MMC and PM.
Dicumarol did increase the resistance of GM38, but not to the same level of resistance demonstrated by
3437T. These results suggest that the aerobic MMC and PM resistance of 3437T may arise, in part, from a
deficiency in DT-diaphorase activity. The identical sensitivities under hypoxic conditions indicate that drug
activation pathways operative in the absence of oxygen are similar in both the normal and 3437T cells.
Bioreductive alkylating agents, such as the antitimour agent
mitomycin C (MMC) and a closely related analogue, por-
firomycin (PM), may be useful in increasing local control of
solid neoplasms when utilised in conjunction with radiation
(Rockwell, 1983; Rockwell & Sartorelli, 1989). The basis of
this assumption lies in the preferential toxicity of these
agents towards hypoxic cells, a population which is refrac-
tory to treatment with radiation and some chemotherapeutic
agents.
While preferential hypoxic cell toxicity appears to arise
from increased reduction of the parent molecule to reactive
intermediates under conditions of poor oxygenation
(Kennedy et al., 1980, 1982), the precise enzymatic pathways
by which these agents are activated, under either hypoxic or
aerobic conditions, have yet to be elucidated. Furthermore,
the majority of data which demonstrate hypoxic cell selec-
tivity have been obtained in murine systems, both in vitro
and in vivo. While few human cell strains have been investi-
gated for hypoxic cell selectivity, one report demonstrated no
statistically significant enhancement of MMC cytotoxicity
under hypoxic conditions in a series of human tumour
samples (Ludwig, 1984). It was suggested that this may
result from the absence of an oxygen-sensitive, MMC-
metabolising enzyme system in human cells.
Development of drug resistance may also limit the clinical
utility of this class of compounds. Model cellular systems
have been established and utilised to investigate the causes
and characteristics of MMC resistance in human cells (Long
et al., 1984; Dorr et al., 1987). Analogues of MMC have
been synthesised to overcome experimentally induced and
naturally occurring resistance (Willson et al., 1985;
Chakrabarty et al., 1986). However, to date such investi-
gations have been concerned solely with resistance occurring
in aerobic cell populations and development of analogues to
overcome such aerobic resistance.
The present work examines the hypoxic and aerobic
cytotoxicity of MMC and PM toward two non-transformed
human skin fibroblast strains. One of these strains was
derived from a healthy donor (GM38) and the other from a
member of a cancer-prone family (3437T). This study was
undertaken primarily to determine if human cells were more
sensitive to these agents under hypoxic conditions. The
observation that strain 3437T cells were resistant to MMC
under aerobic conditions (Paterson et al., 1986) permitted an
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investigation of the toxicity of a MMC analogue, PM,
towards MMC-resistant cells, as well as an examination of
the aerobic/hypoxic differential cytotoxicity displayed by a
drug-resistant cell population.
Cellular resistance to bioreductive alkylating agents may
result from a variety of factors, including altered drug
permeability, decreased drug activation or increased repair of
lesions. Since MMC and PM are believed to exert their
cytotoxic effect primarily through the introduction of inter-
strand DNA-DNA cross-links (Iyer & Szybalski, 1963),
resistance could arise from an increase in the ability of the
cell to repair cross-links. To investigate this possibility the
sensitivity of these cell strains to another chemotherapeutic
agent (cisplatin) capable of cross-link formation (Rahmouni
& Leng, 1987; Pinto & Lippard, 1985 and references cited
therein; Plooy et al., 1985) was examined.
The requirement for metabolic activation of the parent
molecule to a cytotoxic species suggests a different method
for the generation of MMC-resistance. Reduced production
of alkylating species might reflect such deficiencies in activa-
tion and has been examined in these cell strains (Marshall et
al., 1989). While the enzymology of the reductive activation
of these compounds is poorly understood, dicumarol, a
specific inhibitor of the enzyme DT-diaphorase, is able to
reduce mitomycin C cytotoxicity in murine cells (Keyes et
al., 1985a,b). In this report we have examined the effect of
this enzyme inhibitor on the cytotoxicity of MMC and PM
in two non-transformed human skin fibroblasts which differ
with respect to their response to MMC under aerobic
conditions.
Materials and methods
Cells
The non-transformed cell strains utilised in these experiments
were established from human skin explants as described by
Paterson et al. (1986). The cell strain GM38 (NIGMS
Human Genetic Mutant Cell Repository, Camden, NJ), was
derived from a healthy 9-year-old female donor and
characteristically demonstrated plating efficiencies of 30 +8%
(n=8). The cell strain 3437T was obtained from a female
patient belonging to a family prone to multiple polyposis
and sarcomas who had developed two malignancies. The
plating efficiency of this strain was routinely 20+2% (n=9).
Monolayers of cells were grown in a-minimum essential
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medium with 10% fetal bovine serum (FBS) (Bocknek
Laboratories Inc., Canada) (growth medium) in 175cm2
polystyrene tissue culture flasks (Nunclon, Denmark) and
subcultured in a 1:4 dilution once they had reached con-
fluence. All experiments were conducted between passages 20
and 26 and both cell strains were at identical passage
number. Results did not vary within the passage range
utilised (data not shown).
Chemicals
Lyophilised mitomycin C (Boehringer Mannheim, FRG),
porfirmoycin (gift from Upjohn Pharmaceutical Co., Kala-
mazoo, MI) and cisplatin (Frank Horner Inc., Canada)
were reconstituted with sterile deionised water and used
immediately (cisplatin) or within seven days (MMC and
PM), during which time there was no loss of drug activity.
MMC and PM were also checked spectrophotometrically
before each experiment to confirm concentrations. Di-
cumarol was obtained from Sigma Chemical Co. (St Louis,
MO) and dissolved with stoichiometric amounts of NaOH in
sterile, deionised water.
Drug exposure to monolayer cultures
Seventy-two hours before subjecting cell monolayers to drug
treatments, 100mm polystyrene tissue culture dishes (Nun-
clon, Denmark) were inoculated with heavily irradiated
(50Gy) feeder cells of the same strain. Appropriate numbers
of experimental cells were seeded in the same dishes 24 hours
before drug addition so that the total number of irradiated
and non-irradiated fibroblasts was 6 x 104 per dish. Drugs
were diluted to appropriate concentrations in a-MEM plus
10% FBS immediately before exposures. Growth medium
was removed from the plates and replaced with 10ml of
growth medium containing the appropriate drug concen-
tration, and cells were exposed for 1 hour at 37°C in a
humidified atmosphere of 5% CO2:95% air. At the end of
the exposure period the drug was removed, the plates were
each washed with 10ml of growth medium, and 10ml of
growth medium was added to each plate. Growth medium
was changed every 5 days during subsequent incubation and
colonies were counted after 15 days. When desired, di-
cumarol was added to the drug-containing medium to a final
concentration of either 1.0 or 2.0 mM immediately before
drug exposure. These concentrations of dicumarol alone had
100
no effect on the plating efficiency of either cell strain (data
not shown).
Drug exposure to suspension cultures
Cultures containing roughly Sx 106 cells were harvested
from each flask with a 0.25% trypsin solution (Gibco
Laboratories). Cells were pelleted by centrifugation at 240g
for 5min and resuspended in growth medium to a final cell
density of 1 x 106ml-1. Exposure of suspensions was con-
ducted as described previously (Marshall & Rauth, 1986).
Briefly, 10ml of the cell suspension was continually stirred in
a stoppered glass vial with gas containing either 5%
CO2:95% air or 5% CO2: balance N2: <lOp.p.m. 02 (Gas
Dynamics Inc., Canada) flowing over the suspension surface.
Cell suspensions were equilibrated for 1 hour and then 0.1 ml
of drug was added to each vial to give a final concentration
of 0.5pgml-1. Samples were removed as a function of time
after drug addition without altering the oxygen tension in
solution, as monitored with an electronic oxygen sensor
(Marshall et al., 1986). Cells were removed from drug-
containing medium by centrifugation, resuspended and
added to plates containing heavily irradiated feeder cells so
that the final number was 6 x 104 per plate. Incubations were
as described for monolayer culture experiments with cell
colony forming ability being assessed after 15 days.
Results
As previously described, the cell strain 3437T was derived
from a member of a multiple polyposis-sarcoma prone
family (Paterson et al., 1986). To investigate the sensitivity of
this cell strain to bioreductive alkylating agents, GM38 and
3437T cells were initially exposed in monolayers to various
concentrations of MMC for I hour. As demonstrated in
Figure 1, the 3437T strain was six times more resistant to an
aerobic exposure to MMC than the control strain, GM28.
The doses of MMC required to reduce relative plating
efficiency to 10% (DIo) for 3437T and GM38 were 0.5 and
3.0pg ml-1 h-1, respectively.
Porfiromycin is an analogue of MMC which is less toxic
toward rodent cells under aerobic conditions but at least as
toxic under hypoxic conditions (Keyes et al., 1985a,b;
Fracasso & Sartorelli, 1986). To determine whether GM38
and 3437T cells would also be less sensitive to PM than
MMC under aerobic conditions the cells were exposed to
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Figure 1 Relative plating efficiency of control (GM38) (conti-
nuous line) and MMC resistant (3437T) (dotted line) human skin
fibroblasts in monolayer after a I hour exposure under aerobic
conditions to various concentrations of MMC. Cell strain 3437T
is roughly six times more resistant to such exposures than GM38.
Different symbols indicate separate experiments.
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Figure 2 Relative plating efficiency of control (GM38) (solid
line) and MMC resistant (dotted line) (3437T) human skin
fibroblasts in monolayer afer a hour exposure under aerobic
conditions to various concentrations of PM. Strain 3437T is
seven times more resistant than GM38. Different symbols indi-
cate separate experiments.
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PM in the same fashion as described for MMC. Consistent
with results obtained with transformed cells of rodent origin,
PM was found to be less toxic than MMC under aerobic
conditions towards human fibroblasts (Figure 2). As well,
3437T cells were seven-fold more resistant to PM than the
GM38 strain. The Dios were 3.0 for GM38 and
20pgml-1h-1 for 3437T. Thus, increased survival of the
resistant strain over that of the control strain was observed
for both MMC and PM.
The clinical importance of bioreductive alkylating agents
may lie in their potential to kill selectively hypoxic tumour
cells rather than normal, well-oxygenated cells. While selec-
tive hypoxic toxicity has been well documented in rodent
systems in vitro, little evidence has been provided to suggest
that this potential for selective toxicity is seen with human
cells. Also, it is not known whether cells resistant to
bioreductive alkylating agents under aerobic conditions are
also resistant under hypoxic conditions. To investigate these
questions GM38 and 3437T cells were suspended in growth
media under either hypoxic (<l10p.p.m. oxygen) or aerobic
(21% oxygen) conditions during exposure to 0.5pg ml-' of
either MMC or PM for different periods of time. Again, a
six-fold increase in resistance to MMC of 3437T compared
to GM38 fibroblasts was observed under aerobic suspension
conditions (Figure 3). As previously noted for other cell
lines, MMC demonstrated increased toxicity towards both
GM38 and 3437T strains when exposures were conducted
under hypoxic conditions. However, the MMC resistance
demonstrated by 3437T relative to normal fibroblasts under
aerobic conditions was lost under hypoxic conditions. An
increase in sensitivity to MMC under hypoxic conditions was
observed for 3437T compared to GM38 cells, but the
difference was small (1.4-fold).
As shown in Figure 4, exposure of these cell strains in
suspension to PM under either aerobic or hypoxic conditions
yielded results qualitatively similar to those for MMC. As
observed in the monolayer system (Figure 2), PM was less
toxic than MMC towards both cell lines under aerobic
conditions. Also, 3437T was more resistant than GM38. PM
was more toxic to both cell strains under hypoxic conditions,
and the resistance of 3437T, relative to GM38, disappeared
under such conditions. The toxicity of PM under hypoxic
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Figure 4 Survival of human fibroblasts in suspension as a
function of exposure time to 0.5pgml 1 PM under aerobic (open
symbols) and hypoxic conditions (filled symbols). Strain 3437T is
more resistant under aerobic conditions only.
conditions was almost identical to that observed for MMC
at equimolar levels, in contrast to the increased toxicity
observed in rodent cell lines under hypoxic conditions (Keyes
et al., 1985a,b; Fracasso & Sartorelli, 1986).
Resistance to bioreductive alkylating agents may arise
from enhanced repair of the resulting lethal lesions. Inter-
strand DNA cross-links are the apparent lethal lesion pro-
duced by both PM and MMC. To determine whether
increased ability to repair DNA cross-links leads to the
increased aerobic resistance of 3437T to these agents, res-
ponse to cisplatin, a cross-linking agent which does not
require metabolic activation, was investigated. The two cell
strains were exposed to various concentrations of cisplatin
in monolayers in the same fashion as described for MMC in
Figure 1. Figure 5 demonstrates that GM38 and 3437T were
almost identical in their sensitivities to cisplatin, suggesting
that enhanced repair of interstrand cross-links was not
responsible for the resistant phenotype of 3437T.
The failure of 3437T to demonstrate enhanced resistance
under hypoxic conditions suggested that its resistance might
arise from an inability to activate these agents under aerobic
conditions. Dicumarol is an agent which inhibits the aerobic
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Figure 3 Survival of human fibroblasts in suspension as a
function of exposure time to 0.5pgml-1 MMC under aerobic
(open symbols) and hypoxic conditions (filled symbols). While
strain 3437T is more resistant than strain GM38 to aerobic
exposures, this selective resistance is lost under hypoxic
conditions.
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Figure 5 Relative plating efficiency of GM38 (filled symbols)
and 3437T (open symbols) human skin fibroblasts after a I hour
aerobic exposure in monolayer to various concentrations of
cisplatin. Points are averages of at least three experiments
+s.e.m.
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Figure 6 Relative plating efficiency of GM38 and 3437T cells
after 1 hour exposures to various MMC concentrations in the
presence or absence of 1.0 or 2.0mM dicumarol. Addition of
dicumarol had no effect at either level on the survival of 3437T,
but protected GM38. Exposures were conducted under aerobic
conditions in monolayer.
activation of MMC and PM, probably through its inhibition
of DT-diaphorase, an enzyme involved in the aerobic activa-
tion of these compounds (Keyes et al., 1984). Dicumarol
does not alter drug uptake under aerobic conditions in
mouse EMT6 cells (Keyes et al., 1986). If deficient aerobic
activation was a cause of resistance it would be expected that
blocking a potential activation pathway with dicumarol
could increase resistance of the GM38 fibroblasts while
having little or no effect on the sensitivity of 3437T fibro-
blasts. GM38 and 3437T cells were exposed in monolayers to
various concentrations of MMC under aerobic conditions in
the absence or presence of 1.0 or 2.0mM dicumarol. Di-
cumarol increased the resistance of the control fibroblasts to
MMC but had no effect on the resistance of the 3437T cells
(Figure 6). Below MMC concentrations of jugml-1 the
protective effect for GM38 was identical for either 1 or 2 mM
dicumarol. At higher MMC concentrations the protective
effect was greater for 2 mM dicumarol.
Discussion
Preferential hypoxic cell toxicity of bioreductive alkylating
agents has been demonstrated previously in rodent cells
(Kennedy et al., 1980; Marshall & Rauth, 1986). While it has
been assumed that such selectivity could also be obtained in
human cells, no increase in cytotoxicity of MMC under
hypoxic conditions was observed in a series of human
tumour samples (Ludwig, 1984). In the present work, non-
transformed, human skin fibroblasts were significantly more
sensitive to both MMC and PM under hypoxic than under
aerobic conditions (Figures 3 and 4). It would appear,
therefore, that while preferential hypoxic cytotoxicity occurs
in cells of human origin, the ability to demonstrate this
characteristic may depend on several factors. Variations
between cell lines and differences in actual oxygen concen-
tration under hypoxic conditons may alter the degree of
preferential toxicity observed (Marshall & Rauth, 1986;
Gupta & Constanzi, 1987). Other variables which may also
be important in such comparisons include drug concen-
tration, duration of drug exposure, cell density, presence or
absence of agents which selectively modify cytotoxicity and
metabolic state of the cells (Rockwell, 1986; Marshall &
Rauth, 1986; Gupta & Constanzi, 1987).
Development of drug resistance in a tumour may be a
significant barrier to curability. It is notable, therefore, that
the aerobic resistance to either MMC or PM demonstrated
by the cell strain 3437T, compared to the normal cell strain
GM38, is absent under hypoxic conditions (Figures 3 and 4).
Clinically, bioreductive alkylating agents might be combined
with radiation in order to increase local control of specific
solid tumours in which radioresistant hypoxic populations
are a limiting factor (Rockwell & Sartorelli, 1989). The loss
of MMC resistance under hypoxic conditions would suggest
that drug resistance of aerobic cell populations may not
always be a limitation to this form of combined therapy. It
also suggests that the activity of bioreductive alkylating
agents should be examined under hypoxic, as well as aerobic,
conditions. MMC-resistant variants of a human colonic
carcinoma have recently been derived and characterised
under aerobic conditions (Long et al., 1984; Dorr et al.,
1987). Analogues of MMC have also been synthesised and
characterised with respect to their cytotoxicity toward such
resistant populations under aerobic conditions (Willson et
al., 1985; Chakrabarty et al., 1986). It was therefore of
interest to examine the activity of these analogues against a
resistant cell strain under hypoxic conditions to determine
whether preferential cytotoxicity could be obtained,
especially if they are to be combined with ionising radiation
for treatment of solid tumours.
Porfiromycin is one MMC analogue which has been found
to be less toxic towards aerobic and at least as toxic towards
hypoxic murine cells when compared to MMC (Keyes et al.,
1985; Fracasso & Sartorelli, 1986). In the present study it
was found that PM was less toxic towards aerobic human
cells than MMC, but equitoxic under hypoxic conditions.
Cells which were resistant to MMC under aerobic conditions
were similarly resistant to PM. Therefore, this analogue
might demonstrate an enhanced therapeutic ratio, as an
adjunct to radiation therapy, as a result of decreased toxicity
towards normal, well-oxygenated tissue without loss in
hypoxic cytotoxicity.
Cellular resistance to MMC and PM may occur by at least
four different mechanisms. (1) Mutants have been isolated
with are deficient in the repair of DNA-DNA cross-links
and exquisitely sensitive to MMC (Thomson et al., 1980;
Meyn et al., 1982), suggesting that enhanced repair of DNA
cross-links could lead to increased drug resistance. (2) Bio-
reductive alkylating agents require metabolic activation
before demonstrating cytotoxicity, so that a deficiency in the
enzymatic pathways responsible for such activity would also
lead to less cellular damage and apparent drug resistance. (3)
Altered levels of intracellular protective agents such as
glutathione. (4) Decreased drug transport arising from
membrane alterations may protect against cytotoxicity.
If MMC resistance of the 3437T cells was to result from
enhanced repair of DNA cross-links, resistance might also be
observed upon exposure to other cross-linking agents. Resist-
ant and control human fibroblasts utilised in these experi-
ments demonstrated no difference in their sensitivity to cis-
platin, another chemotherapeutic agent known to introduce
interstrand DNA cross-links. While both MMC and cis-
platin produce a variety of lesions, such as DNA and protein
adducts, DNA-protein cross-links and both inter- and
intrastrand DNA cross-links, interstrand DNA cross-links
are closely associated with observed cytotoxicity (Pinto &
Lippard, 1985; Plooy et al., 1985). The observation that
mutants sensitive to both MMC and cisplatin are also
deficient in the repair of interstrand DNA cross-links sug-
gests also that the modes of toxicity of these agents may be
similar (Meyn et al., 1982). In other studies, there were no
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differences in cytotoxicity between 3437T and GM38 after
exposure to another cross-linking agent, MNU (Paterson et
al., 1986). While each of these agents introduces DNA-DNA
cross-links, only MMC and PM require reductive activation
before generation of reactive, DNA-damaging species. It has
*been demonstrated previously that the MMC resistant 3437T
cells accumulate fewer DNA cross-links than a comparable
normal cell strain after an equivalent dose of MMC
(Paterson et al., 1986). Normal sensitivity to other cross-
linking agents suggests that this is not due to an increase in
the repair of cross-links. Together, these data suggest that
increased repair of interstrand DNA cross-links is not the
reason for the observed resistance to MMC and PM and
suggest that deficient activation of these compounds may be
responsible.
Cellular enzymes implicated in the activation of mitomycin
compounds include xanthine oxidase, cytochrome c reductase
and DT-diaphorase (NAD(P)H dehydrogenase) (Pan et al.,
1984; Keyes et al., 1984). Exposure to either PM or MMC
under hypoxic conditions increases the level of cytotoxicity
in both cell strains to the same level, eliminating the resistant
phenotype demonstrated by 3437T under aerobic conditions.
These results suggest that MMC resistance in the 3437T cells
results from deficient drug activation under aerobic, but not
hypoxic, conditions. While the relative importance of each
system under hypoxic and/or aerobic conditions remains
unclear, DT-diaphorase appears to be involved in aerobic
activation (Keyes et al., 1984).
It was found that dicumarol, an inhibitor of DT-
diaphorase, was able to modify the aerobic MMC sensitivity
of normal, but not resistant, human fibroblasts. The relati-
vely high concentrations of dicumarol used in these studies
were based upon previous aerobic cell survival studies by
Keyes et al. (1986) in which surviving fraction increased as
dicumarol concentration increased from 0.03 to 1.OmM. The
observation that 2mM dicumarol provided enhanced protec-
tive effects relative to 1 mM dicumarol only at higher MMC
concentrations (Figure 6) may indicate a saturation of
dicumarol's protective effect at low MMC concentrations.
The poor solubility of dicumarol prevented investigation of
this effect at higher concentrations. However, the ability of
dicumarol to increase the level of aerobic resistance of the
control but not the resistant cells suggested that a deficiency
in DT-diaphorase (NAD(P)H dehydrogenase), an enzyme
capable of 2-electron, aerobic reduction of quinone com-
pounds (lyanagi & Yamazaki, 1970), was partially respon-
sible for the aerobic MMC resistance demonstrated by the
3437T cells. Indeed, initial measurements using the method
of Benson et al. (1980) indicate that substantial levels of DT-
diaphorase activity are present in GM38 cells
(1830+220nmol min-' mg protein-'), with little activity
being detected in the 3437T cells (30+20nmol min-' mg
protein -1).
While dicumarol is a specific inhibitor of DT diaphorase
(Ernster et al., 1962), the concentration utilised in these
experiments may also have some effect upon respiration
(Conover & Ernster, 1962) and intracellular calcium homeo-
stasis (Thor et al., 1982). However, such alternations might
be expected to increase rather than decrease the cytotoxic
effects of MMC, as was found by Thor et al. (1982) in the
exposure of rat hepatocytes to both dicumarol and mena-
dione. These effects of dicumarol may be responsible for the
increased hypoxic cytotoxicity of MMC observed by
Fracasso & Sartorelli (1986), however, the present data are
unable to address this question. An examination of the
effects of dicumarol on the hypoxic cytotoxicity of MMC to
strains GM38 and 3437T might provide further evidence to
support this mechanism for increased toxicity.
Addition of dicumarol to GM38 during MMC exposures
did not completely mimic the drug-resistant phenotype. This
may suggest either that external addition of this agent does
not completely inhibit intracellular DT-diaphorase activity,
or that additional factors are involved in the aerobic resis-
tance of 3437T. No over-expression of P-glycoprotein, a
membrane protein associated with pleiotropic drug resistance
(Kartner et al., 1983), was observed in the 3437T cells (data
not shown). It is possible, however, that another factor
involved with aerobic drug transport may be altered in these
cells (Taylor et al., 1985; Willson et al., 1984). Transport of
these agents under hypoxic conditions appears to be more
rapid than under aerobic conditions (Keyes et al., 1987).
Whether this is a result of enhanced diffusion gradients due
to increased intracellular drug metabolism or differences in
transport related to hypoxia is unclear. The current results
would be consistent with a model in which MMC transport
is different under aerobic versus hypoxic conditions, such
that an alteration in an aerobic but not hypoxic transport
mechanism(s) could occur.
Conflicting reports in the literature make it difficult to
attribute the aerobic drug resistance to altered levels of
intracellular protective agents (Shrieve & Harris, 1986;
Geard & Georgsson, 1986). If gluthathione does modulate
MMC and PM cytotoxicity it may be possible that increased
levels play a role in the aerobic resistance observed in these
cells.
While these observations provide evidence for the existence
of at least two separate and distinct pathways of bioreduc-
tive activation under aerobic and hypoxic conditions, other
factors which may also contribute to MMC resistance, such
as altered transport or increased levels of intracellular pro-
tective agents, have not been eliminated. Detailed studies of
DT-diaphorase levels and the possible contribution of altered
drug transport and glutathione levels to MMC resistance in
these cell strains are in progress.
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